PharmaCenter Bonn, Pharmaceutical Institute, Department of Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany.
Institute of Bioanalytical Chemistry, Center for Biotechnology and Biomedicine, Leipzig University, Deutscher Platz 5, D-04103 Leipzig, Germany.
J Med Chem. 2020 Mar 26;63(6):2941-2957. doi: 10.1021/acs.jmedchem.9b01611. Epub 2020 Feb 28.
CD73 inhibitors are promising drugs for the (immuno)therapy of cancer. Here, we present the synthesis, structure-activity relationships, and cocrystal structures of novel derivatives of the competitive CD73 inhibitor α,β-methylene-ADP (AOPCP) substituted in the 2-position. Small polar or lipophilic residues increased potency, 2-iodo- and 2-chloro-adenosine-5'--[(phosphonomethyl)phosphonic acid] (, ) being the most potent inhibitors with values toward human CD73 of 3-6 nM. Subject to the size and nature of the 2-substituent, variable binding modes were observed by X-ray crystallography. Depending on the binding mode, large species differences were found, e.g., 2-piperazinyl-AOPCP () was >12-fold less potent against rat CD73 compared to human CD73. This study shows that high CD73 inhibitory potency can be achieved by simply introducing a small substituent into the 2-position of AOPCP without the necessity of additional bulky -substituents. Moreover, it provides valuable insights into the binding modes of competitive CD73 inhibitors, representing an excellent basis for drug development.
CD73 抑制剂是癌症(免疫)治疗有前途的药物。在这里,我们介绍了新型竞争性 CD73 抑制剂 α,β-亚甲基-ADP(AOPCP)的 2-位取代物的合成、结构-活性关系和共晶结构。在 2-位引入小极性或亲脂性残基可以提高活性,2-碘代和 2-氯腺苷-5'-[[(膦酸甲基)膦酸](,)是最有效的抑制剂,对人 CD73 的 值为 3-6 nM。受 2-取代基的大小和性质的影响,通过 X 射线晶体学观察到可变的结合模式。根据结合模式,发现了很大的种间差异,例如,2-哌嗪基-AOPCP()对大鼠 CD73 的活性比对人 CD73 的活性低 12 倍以上。这项研究表明,通过在 AOPCP 的 2-位简单引入一个小取代基,而无需额外的大体积 -取代基,就可以实现高 CD73 抑制活性。此外,它为竞争性 CD73 抑制剂的结合模式提供了有价值的见解,为药物开发提供了极好的基础。